We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 03, 2021

Patient Preference Between Cabazitaxel and Docetaxel for First-Line Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

European Urology

 

Additional Info

European Urology
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
Eur Urol 2021 Nov 14;[EPub Ahead of Print], G Baciarello, R Delva, G Gravis, Y Tazi, P Beuzeboc, M Gross-Goupil, E Bompas, F Joly, C Greilsamer, TNT Hon, P Barthelemy, S Culine, JF Berdah, M Deblock, R Ratta, A Flechon, C Cheneau, A Maillard, G Martineau, I Borget, K Fizazi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading